FY2024 EPS Estimate for Stoke Therapeutics Raised by Analyst

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Equities researchers at HC Wainwright raised their FY2024 earnings per share (EPS) estimates for Stoke Therapeutics in a report issued on Wednesday, November 6th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($2.00) per share for the year, up from their prior forecast of ($2.11). HC Wainwright currently has a “Buy” rating and a $35.00 target price on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.10) per share. HC Wainwright also issued estimates for Stoke Therapeutics’ FY2025 earnings at ($2.82) EPS, FY2026 earnings at ($2.09) EPS, FY2027 earnings at ($0.70) EPS and FY2028 earnings at $0.22 EPS.

Stoke Therapeutics (NASDAQ:STOK) last announced its earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.05. The company had revenue of $4.89 million for the quarter, compared to analysts’ expectations of $3.46 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%.

Several other brokerages have also recently weighed in on STOK. Leerink Partnrs upgraded Stoke Therapeutics to a “strong-buy” rating in a report on Friday, October 11th. Needham & Company LLC reissued a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday. Finally, Leerink Partners started coverage on Stoke Therapeutics in a report on Monday, October 14th. They issued an “outperform” rating and a $18.00 target price for the company. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Stoke Therapeutics presently has an average rating of “Buy” and an average target price of $20.83.

Stoke Therapeutics Trading Up 4.6 %

STOK opened at $13.88 on Friday. The firm has a market capitalization of $735.22 million, a PE ratio of -6.61 and a beta of 0.95. Stoke Therapeutics has a twelve month low of $3.77 and a twelve month high of $17.58. The firm’s 50-day moving average price is $13.21 and its 200 day moving average price is $13.72.

Insider Buying and Selling

In other Stoke Therapeutics news, major shareholder Skorpios Trust sold 1,937,500 shares of Stoke Therapeutics stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $14.05, for a total value of $27,221,875.00. Following the sale, the insider now owns 8,906,181 shares in the company, valued at $125,131,843.05. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 11.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Quest Partners LLC acquired a new stake in Stoke Therapeutics in the 2nd quarter valued at about $29,000. Nisa Investment Advisors LLC boosted its position in shares of Stoke Therapeutics by 53.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock worth $40,000 after acquiring an additional 1,038 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Stoke Therapeutics during the second quarter worth approximately $123,000. State Board of Administration of Florida Retirement System acquired a new stake in Stoke Therapeutics during the first quarter worth approximately $141,000. Finally, Intech Investment Management LLC purchased a new position in shares of Stoke Therapeutics in the 3rd quarter valued at $160,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.